GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » Revenue

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Revenue : ¥600.5 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co Revenue?

Wuhan Hiteck Biological Pharma Co's revenue for the three months ended in Jun. 2024 was ¥152.7 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was ¥600.5 Mil. Wuhan Hiteck Biological Pharma Co's Revenue per Share for the three months ended in Jun. 2024 was ¥1.09. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was ¥4.44.

Warning Sign:

Wuhan Hiteck Biological Pharma Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Wuhan Hiteck Biological Pharma Co was -12.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -2.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -3.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was -4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 11 years, Wuhan Hiteck Biological Pharma Co's highest 3-Year average Revenue per Share Growth Rate was 21.60% per year. The lowest was -16.70% per year. And the median was -3.10% per year.


Wuhan Hiteck Biological Pharma Co Revenue Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co Revenue Chart

Wuhan Hiteck Biological Pharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 620.16 524.12 614.68 688.63 602.28

Wuhan Hiteck Biological Pharma Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.81 151.98 163.86 131.89 152.74

Competitive Comparison of Wuhan Hiteck Biological Pharma Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Hiteck Biological Pharma Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Hiteck Biological Pharma Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wuhan Hiteck Biological Pharma Co's Revenue distribution charts can be found below:

* The bar in red indicates where Wuhan Hiteck Biological Pharma Co's Revenue falls into.



Wuhan Hiteck Biological Pharma Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥600.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Hiteck Biological Pharma Co  (SZSE:300683) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Wuhan Hiteck Biological Pharma Co Revenue Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Hiteck Biological Pharma Co Business Description

Traded in Other Exchanges
N/A
Address
Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Executives
Yan Jie Director
Li Sheng Qiang Executives

Wuhan Hiteck Biological Pharma Co Headlines

No Headlines